A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 4, 2002, Pages 1797-1804

  Parkinson, C ^a,b,c   Drake, W M ^a,b   Roberts, M E ^a,c   Meeran, K ^b,c   Besser, G M ^a,b,c   Trainer, P J ^a,b,c  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; GASTRIN; GASTROINTESTINAL HORMONE; GLUCOSE; INSULIN; OCTREOTIDE; PANCREAS POLYPEPTIDE; PEGVISOMANT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ACROMEGALY; ADULT; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIMERIZATION; DRUG BLOOD LEVEL; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HORMONE RESPONSE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; MALE; MEAL; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION;

EID: 0036284407     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.4.8432     Document Type: Article

References (65)

1. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone
2. Somatostatin
3. Distribution of somatostatin receptors in normal and tumor tissue
4. Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylylcyclase
5. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney
6. Somatostatin receptors, an expanding gene family: Cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase
7. Molecular cloning and functional expression of a brain-specific somatostatin receptor
8. Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28
9. Characterization of cloned somatostatin receptors SSTR4 and SSTR5
10. All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase
11. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5)
12. Molecular pharmacology of somatostatin-receptor subtypes
13. Octreotide treatment of acromegaly. A randomized, multicenter study
14. A prospective multicenter octreotide dose response study in the treatment of acromegaly
15. Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - A clinical research center study
16. Octreotide
17. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide
18. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status
19. Results of a European multicentre study with Sandostatin LAR in acromegalic patients
20. Somatostatin and octreotide in gastroenterology
21. Effect of the somatostatin analogue Sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men
22. Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR
23. Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization
24. Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a postreceptor site
25. Glucose tolerance and plasma immunoreactive insulin levels in acromegalics before and after selective transsphenoidal surgery
26. Relationship between blood pressure and glucose tolerance in acromegaly
27. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy
28. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly
29. Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly
30. Effect of octreotide on glucose tolerance in acromegaly
31. Criteria for cure of acromegaly: A consensus statement
32. Long-term treatment of acromegaly with pegvisomant, a growth hormone antagonist
33. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
34. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist
35. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs
36. Effect of chymotrypsin on human cholecystokinin release: Use of clostripain in the validation of a new radioimmunoassay
37. Fatty acid chain length determines cholecystokinin secretion and effect on human gastric motility
38. International criteria for the diagnosis of diabetes and impaired glucose tolerance
39. An audit of outcome of treatment in acromegaly
40. Mortality and cancer incidence in acromegaly: A retrospective cohort study
41. Determinants of clinical outcome and survival in acromegaly
42. Epidemiology of acromegaly in the Newcastle region
43. Cardiological aspects of growth hormone and insulin-like growth factor-I
44. Impact of patient's age and disease duration on cardiac performance in acromegaly: A radionuclide angiography study
45. Effects of somatostatin analogue SMS 201-995 in normal man
46. Effect of intravenous somatostatin on jejunal absorption of glucose, amino acids, water, and electrolytes
47. Short-term effects of octreotide on glucose tolerance in patients with acromegaly
48. Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide
49. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: The Whitehall study
50. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease
51. Effect of pegvisomant-induced normalization of serum IGF-I on IGF-II, IGF binding proteins and insulin resistance in active acromegaly
52. Octreotide-associated biliary tract dysfunction and gallstone formation: Pathophysiology and management
53. Gallstones during octreotide therapy
54. Colonic polyps in acromegaly
55. Increased prevalence of colonic adenomas in patients with acromegaly
56. Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly
57. Acromegaly, colonic polyps and carcinoma
58. Does acromegaly really predispose to an increased prevalence of gastrointestinal turnouts?
59. The prevalence and characteristics of colorectal neoplasia in acromegaly
60. Degradation of bile salts by human intestinal bacteria
61. Microbial bile acid transformation
62. Absorption of bile acids from the large bowel in man
63. Unconjugated secondary bile adds in the serum of patients with colorectal adenomas
64. Prolonged large bowel transit increases serum deoxycholic acid: A risk factor for octreotide induced gallstones